Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Celgene) of lenalidomide (Revlimid(®)), as part of the Single Technology Appraisal (STA) process, to submit evidence for the clinical effectiveness and cost-effectiveness of lenalidomide in combination with rituxi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmacoeconomics
Autors principals: Witlox, Willem J. A., Grimm, Sabine E., Riemsma, Rob, Armstrong, Nigel, Ryder, Steve, Duffy, Steven, Carrera, Vanesa Huertas, Posadzki, Pawel, Worthy, Gillian, Pouwels, Xavier G. L. V., Ramaekers, Bram L. T., Kleijnen, Jos, Joore, Manuela A., van Asselt, Antoinette D. I.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2020
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7867510/
https://ncbi.nlm.nih.gov/pubmed/33145711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-020-00971-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars